Literature DB >> 20495469

Nitric oxide, ammonia, and CRP levels in cirrhotic patients with hepatic encephalopathy: is there a connection?

Nikolaos Papadopoulos1, Aspasia Soultati, Constantin Goritsas, Christina Lazaropoulou, Apostolos Achimastos, Adam Adamopoulos, Spyridon P Dourakis.   

Abstract

GOALS: Comparison of nitric oxide (NO) levels in cirrhotic patients with and without hepatic encephalopathy (HE), evaluation of possible correlation between HE and other clinical or laboratory characteristics, and estimation of utilization of NO levels in clinical practice.
BACKGROUND: HE is a neuropsychiatric complication of cirrhosis. The exact pathogenetic mechanisms underlying the presence of HE are not known. However, dysfunction of the NO pathway and ammonia detoxification are thought to play a major role. STUDY: Sixty-seven cirrhotic patients, 36 (53.7%) without HE, and 31 (46.3%) with HE were included in the study. Eighteen healthy individuals were used as control group. Clinical and laboratory data, including ammonia and stable end products of NO using Griess reaction, were collected.
RESULTS: NOx levels were statistically significantly higher in cirrhotic patients (225.5 μmol/L) than in control group [(67.94 μmol/L) (P=0.000)]. NOx levels were, also, statistically significantly higher in patients with HE compared with patients without HE (324.67 μmol/L vs. 141.96 μmol/L, P=0.000). Significant correlation between the presence of HE and NOx, ammonia, C-reactive protein, albumin, Model for End-Stage Liver Disease score, and Child-Pugh classification revealed. NOx levels also correlated with severity of HE. NOx and ammonia are independent factors predicting HE according to regression analysis. Diagnostic accuracy for the diagnosis of HE using a combination of NOx and ammonia was superior compared with standalone NOx or ammonia utilization.
CONCLUSIONS: NOx levels are correlated with the presence and severity of HE. NOx levels determination, in addition to ammonia levels, could contribute in diagnosis of HE.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20495469     DOI: 10.1097/MCG.0b013e3181d47f71

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  6 in total

Review 1.  Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals.

Authors:  Uraina S Clark; Ronald A Cohen
Journal:  Curr Opin Investig Drugs       Date:  2010-08

2.  Gastroesophageal reflux in cirrhotic patients without esophageal varices.

Authors:  Jun Zhang; Pei-Lin Cui; Dong Lv; Shi-Wei Yao; You-Qing Xu; Zhao-Xu Yang
Journal:  World J Gastroenterol       Date:  2011-04-07       Impact factor: 5.742

3.  Nitrogenous compounds in the saliva and blood of cirrhotic patients: a cross-sectional study.

Authors:  Nathália Tuany Duarte; Jefferson R Tenório; Natália Silva Andrade; Fabiana Martins; Marina Gallottini; Karem L Ortega
Journal:  Clin Oral Investig       Date:  2022-02-28       Impact factor: 3.573

4.  Erythromycin versus neomycin in the treatment of hepatic encephalopathy in cirrhosis: a randomized double-blind study.

Authors:  Fernando Gomes Romeiro; Fabio da Silva Yamashiro; Madileine Francely Américo; Luciana Aparecida Corá; Giovanni Faria Silva; José Ricardo de Arruda Miranda; Carlos Antonio Caramori
Journal:  BMC Gastroenterol       Date:  2013-01-16       Impact factor: 3.067

5.  A study on the position and etiology of infection in cirrhotic patients: A potential precipitating factor contributing to hepatic encephalopathy.

Authors:  Qiu-Ming Wang; Qing Ji; Zhi-Jun Duan; Ming Zhang; Qing-Yong Chang
Journal:  Exp Ther Med       Date:  2013-06-03       Impact factor: 2.447

6.  Risk of progression of Barrett's esophagus in patients with cirrhosis.

Authors:  Tehilla Apfel; Rocio Lopez; Madhusudhan R Sanaka; Prashanthi N Thota
Journal:  World J Gastroenterol       Date:  2017-05-14       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.